Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535237 | 0.80 | — | — | |
| SCHEMBL527276 | 0.78 | CYP3A4 (0.43) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL729015 | 0.78 | CYP3A4 (0.43) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL1345378 | 0.78 | CYP3A4 (0.43) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9547228 | 0.77 | MAPT (0.42) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL19033480 | 0.76 | — | — | |
| SCHEMBL4254567 | 0.76 | — | — | |
| SCHEMBL10940301 | 0.76 | — | — | |
| SCHEMBL7359482 | 0.74 | — | — | |
| SCHEMBL9191412 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0885226-A1 | 4-AMINO PYRIMIDINE DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032881-A1 | 4-AMINO PYRIMIDINE DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | claimed |
| EP-0234971-B1 | SUBSTITUTED AMIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC SANTE (FR) | 1990-09-05 | — | — | EP | claimed |
| US-4753933-A | ANXIOLYTIS, ANTIEPILEPTICS, MUSCLE RELAXANTS | RHONE-POULENC SANTE (FR) | 1988-06-28 | — | — | US | claimed |
| EP-1547797-B1 | Lithographic printing plate precursor and lithographic printing method | FUJIFILM CORP (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20070232586-A1 | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof | OHMOTO KAZUYUKI | 2007-10-04 | — | — | US | disclosed |
| EP-1739081-A1 | HYDRAZINO-SUBSTITUTED HETEROCYCLIC NITRILE COMPOUNDS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| EP-1547797-A2 | Lithographic printing plate precursor and lithographic printing method | FUJI PHOTO FILM CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-0885226-A1 | 4-AMINO PYRIMIDINE DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032881-A1 | 4-AMINO PYRIMIDINE DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | disclosed |
| US-4753933-A | ANXIOLYTIS, ANTIEPILEPTICS, MUSCLE RELAXANTS | RHONE-POULENC SANTE (FR) | 1988-06-28 | — | — | US | disclosed |
| US-4753933-A | ANXIOLYTIS, ANTIEPILEPTICS, MUSCLE RELAXANTS | RHONE-POULENC SANTE (FR) | 1988-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232586-A1 | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof | CTRL, PRSS1, CTSZ | CYP3A4 374/4885TSHR 3446/4885MAPT 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.